GlassScriptPhysician profile
Sirvard M Kaptryan
NPI 1841727658
$7,807.13
in general payments reported to CMS, 2019-2025
24 companies · $2,785 in 2025
The $2,785 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.16 · 2022: $222 · 2023: $2,166 · 2024: $2,597 · 2025: $2,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,548.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,704.86 | 2021-2025 | |
| Amgen INC. | $1,000.81 | 2023-2025 | Tavneos, Enbrel, Otezla |
| Glaxosmithkline, LLC. | $754.65 | 2022-2025 | Benlysta, Trelegy Ellipta |
| Ucb, INC. | $703.57 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $683.89 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Aurinia Pharma U.S., INC. | $427.28 | 2022-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $398.87 | 2023-2025 | |
| Pfizer INC. | $375.32 | 2023-2025 | |
| Lilly USA, LLC | $371.95 | 2023-2025 | Taltz, Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $282.24 | 2022-2025 | Saphnelo |
| Ani Pharmaceuticals, INC. | $281.70 | 2023-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.98 | 2024-2025 | Ofev |
| Alexion Pharmaceuticals, INC. | $101.41 | 2023-2025 | Strensiq |
| Biocon Biologics INC | $98.56 | 2024-2025 | Hulio |
| E.R. Squibb & Sons, L.L.C. | $80.47 | 2024-2025 | Orencia |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $66.90 | 2021-2025 | Gazyva, Erivedge |
| Organon LLC | $60.92 | 2024 | |
| Radius Health, INC. | $47.11 | 2023-2024 | |
| Horizon Therapeutics Plc | $42.12 | 2023 | Krystexxa |
| Invivyd INC | $26.36 | 2025 | Pemgarda |
| Sandoz INC. | $25.73 | 2025 | Jubbonti |
| Kiniksa Pharmaceuticals International, Plc | $24.13 | 2024 | Arcalyst |
| Octapharma USA, INC. | $20.60 | 2024 | Octagam Immune Globulin (Human) |
| Kiniksa Pharmaceuticals, LTD. | $13.70 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sirvard Kaptryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.